InfuSystem Hlds

InfuSystem Holdings, Inc. engages in the provision of healthcare services. It operates through the Integrated Therapy Services and Durable Medical Equipment segments. The Integrated Therapy Services segment focuses on providing electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics, and hospital outpatient oncology clinics. The Durable Medical Equipment segment is involved in the rental, sale or leasing of pole-mounted and ambulatory infusion pumps to oncology practices, hospitals, and other clinical settings. The company was founded in August 2005 and headquartered in Rochester Hills, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InfuSystem reports revenue growth but faces supply chain challenges

InfuSystem's Q4 2022 performance showed revenue growth but a decrease in adjusted EBITDA, with a focus on strategic partnerships and conservative guidance for 2023.
The company faces challenges with supply chain issues, reporting delays, and internal control deficiencies, but is actively addressing these issues.
Opportunities lie in expanding the supplier base, enhancing product offerings, and expecting gradual revenue growth in 2023, supported by key partnerships and growth initiatives.

InfuSystem reports record Q1 revenue, expands partnerships for growth

InfuSystem's Q1 2023 performance reflects strong revenue growth, successful partnerships, and strategic expansions, positioning the company for continued success in the healthcare services sector.
While facing challenges such as higher expenses and reimbursement complexities, InfuSystem's focus on innovation and financial stability underscores its resilience and growth potential.
By reaffirming annual guidance and emphasizing sustainable growth strategies, InfuSystem demonstrates a clear vision for driving profitability and market leadership in the coming quarters.

InfuSystem reports robust Q2 earnings, eyes growth in Wound Care

InfuSystem Holdings, Inc. delivered a strong performance in Q2 2023, driven by revenue growth and strategic business decisions. The company's financial results, progress in addressing internal control deficiencies, and raised guidance indicate a positive outlook for future growth. While challenges exist in scaling certain business segments, InfuSystem is well-positioned to capitalize on opportunities in Wound Care and the Sanara joint venture.

InfuSystem reports record Q3 revenue growth and strategic expansion plans

InfuSystem's Q3 2023 performance reflects robust revenue growth, improved profitability, and strategic initiatives for future expansion and operational efficiency.
While facing challenges such as margin pressures and market competition, the company's strengths in oncology and operational enhancements position it for long-term success.
Opportunities in revenue diversification, service expansion, and market presence offer InfuSystem avenues for sustained growth and profitability.
Overall, InfuSystem's strong financial results, strategic focus on growth drivers, and optimism for future performance paint a positive outlook for investors and stakeholders.

InfuSystem Hlds (INFU) reports record revenue in Q4 2023

InfuSystem Hlds (INFU) delivered a robust performance in Q4 2023, showcasing revenue growth and margin improvement. With a strategic focus on core business expansion and operational excellence, the company aims for steady growth in 2024 amidst industry challenges and regulatory changes.

InfuSystem reports strong Q1 revenue growth and strategic partnerships

InfuSystem's Q1 performance reflects revenue growth and profitability improvements driven by operational enhancements.
The company's strategic partnerships and focus on high-potential opportunities position it for sustained growth.
Challenges include market focus shifts and balancing expenses with revenue growth for long-term success.
Overall, InfuSystem's performance outlook remains positive, with confidence in achieving revenue and EBITDA targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InfuSystem Holdings, Inc. engages in the provision of healthcare services. It operates through the Patient Services and Device Solutions segments. The Patient Services segment involves the durable medical equipment, clinic-to-home health care, logistics and billing, and oncology business. The Device Solutions segment includes the sale or rent of new and pre-owned pole-mounted and ambulatory infusion pumps, treatment-related consumables, biomedical recertification, maintenance and repair services for oncology practices. The company was founded by Steven E. Watkins in August 2005 and headquartered in Rochester Hills, MI.

InfuSystem Holdings, Inc. (INFU) Q3 2023 Earnings Call Transcript

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports Third Quarter 2023 Financial Results.

InfuSystem Reports Third Quarter 2023 Financial Results

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Third Quarter 2023 Financial Results on November 7, 2023.

InfuSystem to Report Third Quarter 2023 Financial Results on November 7, 2023

LUND, Sweden , Oct. 4, 2023 /PRNewswire/ -- Scalp cooling innovator Dignitana AB announces today a sales and marketing partnership with  InfuSystem Holdings, Inc.,  a leading health care service provider facilitating outpatient care for durable medical equipment manufacturers and health care providers in the United States. As the preeminent provider of ambulatory infusion pumps and supplies to oncologists and other outpatient infusion centers, InfuSystem is uniquely  suited to offer Dignitana's DigniCap Scalp Cooling System to its customers, enabling easy and efficient ordering and ongoing support to healthcare providers.

Dignitana announces a sales and marketing partnership with InfuSystem to provide scalp cooling systems in the United States

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate in Lake Street's 7th Annual Best Ideas Growth (BIG7) Conference September 14, 2023.

InfuSystem to Participate in Lake Street's 7th Annual Best Ideas Growth (BIG7) Conference September 14, 2023

InfuSystem Holdings, Inc. (NYSE:INFU ) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants Joe Dorame - Managing Partner Richard DiIorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and Chief Operating Officer Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Alex Nowak - Craig-Hallum Capital Group Jim Sidoti - Sidoti & Company Operator Hello, and welcome to the InfuSystem Holdings, Inc. Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.

InfuSystem Holdings, Inc. (INFU) Q2 2023 Earnings Call Transcript

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports Second Quarter 2023 Financial Results.

InfuSystem Reports Second Quarter 2023 Financial Results

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Second Quarter 2023 Financial Results on August 3, 2023.

InfuSystem to Report Second Quarter 2023 Financial Results on August 3, 2023

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Set to Join Russell 3000® Index.

InfuSystem Set to Join Russell 3000® Index

InfuSystem Holdings Inc. (NYSE:INFU ) Q1 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants Joe Dorame - IR, Lytham Partners Richard DiIorio - CEO Barry Steele - CFO Carrie Lachance - President and Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Alexander Nowak - Craig-Hallum Capital Group James Sidoti - Sidoti & Company Operator Good day, and welcome to the InfuSystem Holdings Inc. First Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note that today's event is being recorded.

InfuSystem Holdings Inc. (INFU) Q1 2023 Earnings Call Transcript

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Present at Sidoti Micro-Cap Virtual Conference on May 11, 2023.

InfuSystem to Present at Sidoti Micro-Cap Virtual Conference on May 11, 2023

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports First Quarter 2023 Financial Results.

InfuSystem Reports First Quarter 2023 Financial Results

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report First Quarter 2023 Financial Results on May 4, 2023.

InfuSystem to Report First Quarter 2023 Financial Results on May 4, 2023

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces Distribution Agreement with Genadyne for Negative Pressure Wound Therapy Systems.

InfuSystem Announces Distribution Agreement with Genadyne for Negative Pressure Wound Therapy Systems

INFU has produced impressive growth over the past six quarters, but let down investors during this timeframe because it fell short of its own guidance. In short, INFU's business plans simply took longer to come to fruition than the company expected, so the opportunity for massive growth still exists.

InfuSystem: Disappointing 2022 Results Lead To Bargain Prices

InfuSystem Holdings Inc. (NYSE:INFU ) Q4 2022 Earnings Conference Call March 15, 2023 9:00 AM ET Company Participants Joe Dorame - IR, Lytham Partners Richard DiIorio - CEO Barry Steele - CFO Carrie Lachance - President and Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Alex Nowak - Craig-Hallum Capital Group James Sidoti - Sidoti & Company Operator Good day, and welcome to the InfuSystem Holdings, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.

InfuSystem Holdings Inc. (INFU) Q4 2022 Earnings Call Transcript

InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the fourth quarter and full year ended December 31, 2022.

InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2022

InfuSystem to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023

Intrusion

Perma-Fix Environmental Services

Quipt Home Medical Corp

Smith Micro Software

TechPrecision Corp

2022 was a rough year for most equities, with the S&P down 19% and the Russell 2000 down nearly 22% on the year. In large part because of rough market conditions, several names I cover or follow are at attractive risk/reward levels.

My Top Small-Cap Ideas For 2023

ROCHESTER HILLS, Mich.--( BUSINESS WIRE )--InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that Richard DiIorio, Chief Executive Officer, Barry Steele, Chief Financial Officer, and Carrie Lachance, President and Chief Operating Officer, will participate at Craig-Hallum's 13th Annual Alpha Select Conference on Thursday, November 17, 2022. The conference will be held at the Sheraton New York Times Square in New York City.

InfuSystem to Participate at 13th Annual Craig-Hallum Alpha Select Conference on November 17, 2022

InfuSystem Holdings Inc. (NYSE:INFU ) Q3 2022 Earnings Conference Call November 8, 2022 9:00 AM ET Company Participants Joe Dorame - IR, Lytham Partners Rich DiIorio - CEO Barry Steele - CFO Cary Lachance - President and Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Alex Nowak - Craig-Hallum Capital Group Jim Sidoti - Sidoti & Company Aaron Warwick - Breakout Investors Operator Good day, and welcome to the InfuSystem Holdings, Inc. Reports Third Quarter Fiscal Year 2022 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.

InfuSystem Holdings Inc. (INFU) Q3 2022 Earnings Call Transcript

InfuSystem Reports Third Quarter 2022 Financial Results

Sanara MedTech Inc.

InfuSystem and Sanara MedTech Announce Wound Therapy Partnership

InfuSystem to Report Third Quarter 2022 Financial Results on November 8, 2022

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Appoints R. Rimmy Malhotra to the Board of Directors

News for InfuSystem Hlds Stock (INFU)